+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Kivexa"

US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026 - Product Thumbnail Image

US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026

  • Report
  • February 2021
  • 360 Pages
  • United States
From
Kivexa - API Insight, 2022 - Product Thumbnail Image

Kivexa - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Kivexa- Drug Insight, 2019 - Product Thumbnail Image

Kivexa- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Kivexa is a market of infectious diseases drugs, which are used to treat a variety of illnesses caused by microorganisms such as bacteria, viruses, fungi, and parasites. These drugs are used to treat a wide range of infections, including HIV, malaria, tuberculosis, and influenza. Kivexa drugs are typically administered orally, intravenously, or intramuscularly, depending on the type of infection and the severity of the symptoms. Kivexa drugs are typically prescribed by a doctor or other healthcare professional, and are available in both generic and brand-name forms. The cost of these drugs can vary depending on the type of drug, the dosage, and the manufacturer. Kivexa drugs are an important part of the global effort to combat infectious diseases, as they can help to reduce the spread of these illnesses and improve the quality of life for those affected. Some companies in the Kivexa market include Gilead Sciences, Merck, Pfizer, and GlaxoSmithKline. Show Less Read more